TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.

ABSTRACT: Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer-associated mortality. Recent gene expression profiling has proven successful in predicting the outcome of prostate cancer patients; however, they have yet to provide targeted therapy approaches that could inhibit a patient's progression to metastatic disease.Experimental Design: We have interrogated a total of seven primary prostate cancer cohorts (n = 1,900), two metastatic castration-resistant prostate cancer datasets (n = 293), and one prospective cohort (n = 1,385) to assess the impact of TOP2A and EZH2

SUBMITTER: Labbe DP 

PROVIDER: S-EPMC5690819 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature